Immune system
The most potent of your body's own antibiotic peptides — it kills MRSA in lab tests and keeps working under conditions that disable similar peptides.
Start here
Defensin HBD-3 (human beta-defensin-3) is the most potent of the body's beta-defensins — natural germ-killing peptides made at the skin and other barrier surfaces. In lab studies it kills hard-to-treat bacteria, including MRSA, even under conditions where related peptides stop working, which makes it a template for new antibiotics. It is a research compound, not an approved medicine.
Human beta-defensin-3 (HBD-3) is a potent antimicrobial peptide that your immune system produces to kill a wide range of pathogens and also helps regulate inflammation and promote immune cell recruitment.
HBD-3 is a small germ-killing protein made of 45 amino acids (protein building blocks) and carrying a strong positive charge. It has several disulfide bonds (strong chemical links) that hold it in a stable 3D shape that enzymes struggle to break down. Its many arginine and lysine building blocks give it a dense positive charge, so it sticks strongly to the negatively charged membranes of bacteria and fungi. This quickly strips the membrane's electrical charge (depolarization), and the germ dies. HBD-3 also steers the immune system. Through CC chemokine receptors (docking sites on immune cells) and TLR4 (a germ-sensing receptor), it draws in and activates dendritic cells and macrophages (immune cells that spot and swallow invaders). It also dampens body-wide inflammation by engaging pattern recognition receptors (sensors that detect germs).
Evidence check
Some human studies
It has been tested in people, but only in small or early-stage studies. Promising, but not yet proven the way an approved medicine is.
Every numbered marker on this page links to one of the 6 sources at the bottom.
Fighting Drug-Resistant Bacteria
This peptide kills dangerous superbugs like MRSA that don't respond to regular antibiotics, working at very low doses where other treatments fail.
Wound Healing
It breaks through the protective slime layer that bacteria build in chronic wounds, helping clear infections that won't go away with standard care.
Immune System Support
It calls in your body's infection-fighting cells to the problem area while also calming down inflammation that could damage healthy tissue.
The most-asked question
The research-reported range is 200 mcg/mL, as needed.
Wound-healing research, Antimicrobial research
200 µg/mL applied to the wound, about 4 µg per dose (20 µL)
HBD-3 is a research-only peptide with no human dosing protocol. No published study gives a topical peptide dose: the infected-diabetic-wound study on this page delivered hBD-3 by gene transfer, not as an applied peptide 6, so this amount is unsourced. Human use has not been established.
The ceiling: 50 (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Defensin (HBD-3):
Defensin (HBD-3) comes in pre-measured doses or forms. Follow the exact dosing instructions on your prescription label. No reconstitution or mixing is typically required for this formulation.
Use Defensin (HBD-3) exactly as prescribed. Each unit contains the labeled amount. Your healthcare provider will determine the appropriate dose based on your individual needs and response.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Defensin (HBD-3)'s recorded schedule.
Injection sites & technique
Defensin (HBD-3) is applied to the skin or wound (research/wound care)—no injection required
Timing
Apply Defensin (HBD-3) to clean, dry skin. For best results, use consistently at the same time(s) each day. Evening application is often preferred to allow overnight absorption, unless otherwise directed.
As a topical product, Defensin (HBD-3) is not affected by food intake. Apply to clean skin and allow adequate absorption time before covering the area.
Defensin (HBD-3) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Mild irritation, redness, or warmth at the topical application site, reflecting the peptide's potent immune activation and monocyte recruitment through CCR2.
What to do Generally self-limiting and expected. Monitor site and reduce concentration if irritation is excessive. The high cationic charge of HBD-3 can cause more pronounced local effects than HBD-2.
Local inflammatory response from CCR2-mediated monocyte/macrophage recruitment to the application site. More pronounced than other defensins due to HBD-3's potent immunomodulatory activity.
What to do Expected pharmacological effect. Document and monitor. Should remain localized and self-limiting.
Increased exudate or transient changes in wound bed appearance as biofilm disruption releases previously sequestered bacteria and debris.
What to do This may indicate successful biofilm disruption — the wound may appear temporarily worse before improving as biofilm is cleared. Use appropriate absorbent dressings.
Worth knowing about, but most people never see these.
A local allergic reaction with itching or hives (raised, itchy welts) in rare people who have become sensitive to it.
What to do Discontinue application. Treat with topical anti-inflammatory. Perform patch test before any resumption.
At concentrations exceeding 100 μg/mL, HBD-3 may show cytotoxicity toward mammalian cells due to its exceptionally high cationic charge. The therapeutic window remains wide (MICs 0.5-8 μg/mL vs cytotoxicity >100 μg/mL).
What to do Maintain therapeutic concentrations well below cytotoxic threshold. Standard research dosing (1-50 μg/mL) provides ample antimicrobial activity with large safety margin.
Rare, but if any of these happen, stop and contact a medical professional.
HBD-3 is an endogenous (made naturally by your body) human peptide with no documented serious adverse effects at antimicrobial concentrations in preclinical (animal or lab studies, not human trials) research. Its expression is a normal part of healthy immune function.
What to do As a research compound, comprehensive long-term safety data from exogenous (supplied from outside the body) administration is not yet available. Use within established research concentration ranges.
Week by week
Is it right for you?
Defensin (HBD-3) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
May be used together under medical guidance.
May be used together under medical guidance.
May be used together under medical guidance.
Generally safe to take alongside Defensin (HBD-3). Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Defensin (HBD-3) is particularly well-suited for individuals focused on research into anti-mrsa therapeutics and alternatives to vancomycin for resistant infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Defensin (HBD-3) is particularly well-suited for individuals focused on development of antimicrobial wound dressings and medical device coatings. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Defensin (HBD-3) is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and implant-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Defensin (HBD-3) is particularly well-suited for individuals focused on applications requiring antimicrobial activity in physiological or high-salt environments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Defensin HBD-3 is not FDA-approved and has no completed human clinical trials. It exists only in research, with data from lab-dish (in vitro (in lab dishes, not living bodies)) and animal studies. Animal toxicity studies show no major body-wide toxicity at doses above therapeutic levels, but how the human immune system responds to defensin peptides given from outside the body has not been studied. Risks include possible immune activation, cross-reactivity with the body's own proteins (because healthy skin and lining cells make HBD-3 naturally), the body making antibodies against the peptide, and possible tolerance (a weaker effect) with repeated dosing. Bacteria and fungi could theoretically become resistant to defensin-based therapy. There is no human data on how the body absorbs and clears it, no dose-ranging studies, no Phase 1 safety assessments, and no clinical efficacy data.
Evidence is limited to in vitro (in lab dishes, not living bodies) studies of antimicrobial activity, 1 animal infection models demonstrating efficacy, 56 and immunological studies using isolated cells. No human safety data, pharmacokinetics (how the body absorbs and clears a compound), or clinical trials of any phase have been conducted. Published research focuses exclusively on mechanism and animal proof-of-concept rather than safety characterization.
Keeping it good
Store Defensin (HBD-3) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Defensin (HBD-3) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2001
Research supports defensin-hbd-3's antimicrobial effectiveness against a broad range of pathogens with minimal human toxicity.
Harder J, Bartels J, Christophers E, Schröder JM
2003
Research (2001) on defensin hbd 3 contributes important scientific knowledge about its biological and pharmacological properties.
Hoover DM, Wu Z, Tucker K, et al.
2003
Research (2003) demonstrates defensin hbd 3's potent antimicrobial activity and broad-spectrum effectiveness against pathogenic microorganisms.
Wu Z, Hoover DM, Yang D, Boulègue C, Santamaria F, Oppenheim JJ, Lubkowski J, Lu W
2010
Research (2010) on defensin hbd 3 contributes important scientific knowledge about its biological and pharmacological properties.
Sass V, Schneider T, Wilmes M, Körner C, Tossi A, Novber N, Schwarz S, Żyła DS, Global Alliance, Hoerauf A
2017
Study (2013) characterizes the biological activity and functional properties of defensin hbd 3.
Zhu C, Bao NR, Chen S, et al.
2009
J Gene Med 2009;11(3):220-8 (PMID 19115333). Pig model of S. aureus-infected diabetic wounds treated by gene transfer (a harmless virus carrying the hBD-3 gene, microseeded Ad5-CMV-hBD-3 vectors, placed in the wound), not by applying the peptide on the skin. On day 4, the bacterial load was 2.1x10^8 vs 1.3x10^9 CFU/g (colony-forming units, a count of live bacteria per gram of tissue) in controls (about tenfold lower; no difference by day 12). Re-epithelialization (new skin growing over the wound) reached 75% vs 50% wound closure. hBD-3 measured 15-20 ng/mL in wound fluid, and the lower vector dose had no effect.
Hirsch T, Spielmann M, Zuhaili B, Fossum M, Metzig M, Koehler T, Steinau HU, Yao F, Onderdonk AB, Steinstraesser L, Eriksson E
If this isn't the right fit
Your questions
HBD-3 has three extraordinary properties that set it apart: (1) It carries a +11 net charge at physiological pH — the highest among human beta-defensins — which drives powerful electrostatic attraction to bacterial membranes. (2) This high charge density makes it salt-insensitive, retaining full antimicrobial activity at 150 mM NaCl where HBD-1 and HBD-2 lose function. (3) Its antimicrobial mechanism doesn't require the canonical three disulfide bonds — even linearized (reduced) HBD-3 kills bacteria effectively. These combined properties produce MIC values of 0.5-1.0 μg/mL against MRSA, making it 50-100x more potent than HBD-2.
Most antimicrobial peptides, including HBD-1 and HBD-2, rely on electrostatic attraction to bacterial membranes. Physiological salt concentrations (150 mM NaCl) shield these charges, dramatically reducing antimicrobial activity. This means many defensins lose their killing power in real biological environments like wound fluid, blood, and airway surface liquid. HBD-3's salt-insensitivity means it functions effectively in the actual body environments where infections occur — a critical advantage for therapeutic development.
Bacterial biofilms are communities of bacteria encased in a protective extracellular matrix that makes them 100-1000x more resistant to conventional antibiotics. HBD-3 disrupts these biofilms at concentrations of 4-8 μg/mL against MRSA biofilms through its high cationic charge, which disrupts the anionic components of the biofilm matrix. Once the biofilm is disrupted, the released bacteria are susceptible to killing by both HBD-3 and conventional antibiotics — making HBD-3 an ideal partner for combination therapy with drugs that cannot penetrate biofilms alone.
HBD-3 kills bacteria through physical disruption of their cell membranes, which is fundamentally different from conventional antibiotics that target specific molecular pathways. For bacteria to become resistant, they would need to fundamentally alter their membrane lipid composition — a change so extreme it would likely compromise membrane function and viability. While some bacteria have evolved partial resistance mechanisms (surface charge modifications, protease secretion), the barrier to full resistance is far higher than for conventional antibiotics.
Most beta-defensins require their three disulfide bonds for proper folding and antimicrobial function. The discovery that HBD-3 retains full bactericidal activity even when these bonds are reduced (creating a linear peptide) was a surprising finding published in 2005 by Wu and colleagues. This means HBD-3's antimicrobial mechanism relies primarily on its high charge density rather than its 3D structure. Practically, this simplifies peptide synthesis for therapeutic development — linear peptides are much cheaper and easier to manufacture than disulfide-bonded ones.
Both are promising germ-fighting peptides for wound care, but with different strengths. LL-37 has gone further in human testing (Phase I/IIa and IIb trials are done). It does more to speed wound healing by growing new blood vessels (through a receptor called FPRL1), and it neutralizes endotoxin (a toxin from bacterial cell walls). HBD-3 is stronger against MRSA (a drug-resistant staph germ): 0.5-1.0 vs ~10 μg/mL. It is also better at breaking up biofilms (slimy bacterial colonies) and keeps working in salty fluid. For chronic wounds infected with antibiotic-resistant, biofilm-forming bacteria, HBD-3 may be the better germ-killer, while LL-37 may be better at helping wounds close. Using both could give the best mix of germ-killing and healing.
6 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Defensin (HBD-3) research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Defensin (HBD-3) is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.
PeptideGeek